)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Brain+
Brain+ (BRAINP) investor relations material
Brain+ has been delisted
Brain+ H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary4 Sep, 2025
Executive summary
Achieved significant commercial traction with three UK care home operator contracts, expanding from 7 to 22+ sites, validating the product and market fit.
Clinical validation achieved through a 14-week pilot, showing measurable improvements in resident well-being and staff satisfaction.
Secured NHS dementia innovator accelerator recognition, enhancing credibility and market positioning.
Built a robust UK sales pipeline valued at up to DKK 23 million, with a highly targeted approach to care home operators.
Demonstrated strong leadership commitment and operational focus, with a leaner organization post-restructure.
Financial highlights
Gross profit loss of DKK 1 million for H1 2025, compared to a profit of DKK 1 million last year, mainly due to a halt in capitalized development cost income.
Staff expenses reduced by 16% year-over-year, reflecting restructuring efforts.
Net loss for H1 2025 was DKK 8.0 million, compared to DKK 7.1 million in H1 2024.
Cash position at end of H1 2025 was DKK 4.3 million, bolstered by successful financing rounds.
Cash flow from operating and investing activities was DKK -7.0 million, improved from DKK -7.4 million in H1 2024.
Outlook and guidance
Retains full-year sales contract forecast of DKK 3.6 million, expecting accelerated pipeline conversion.
UK sales pipeline valued at DKK 23 million, with DKK 7.6 million considered closable in 2025.
Probability-weighted 2025 sales cash flow expected at DKK 1.9 million, with a total outlook of DKK 2.2 million for 2025.
Net loss for 2025 now expected at DKK 10.0-11.0 million, higher than previous guidance.
Sufficient funding expected to support operations until mid-2026 cash-flow break-even.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Brain+
- Net loss narrowed, Ayla launched in UK/Denmark, and UK sales pipeline exceeds €600,000.BRAINP
H2 2024 - Robust U.K. sales pipeline and imminent funding needs position for strong commercial growth.BRAINPInvestor Update
- Digital dementia care platform Ayla targets rapid U.K. growth, aiming for break-even by 2026.BRAINPInvestor Update
- Clinically validated digital dementia care platform targets rapid, scalable global growth.BRAINPInvestor Update
- UK launch of digital dementia therapy advances; break-even targeted by end 2025.BRAINPH1 2024
- UK launch of dementia therapy tool on track, with funding secured and strong growth potential.BRAINPInvestor Update
- Secured DKK 5.9M in funding and expanded care home contracts, supporting growth and break-even by 2026.BRAINPStatus Update
- UK dementia care expansion accelerates with rights issue and EUR 500,000 sales pipeline.BRAINPInvestor Update
- 50% of rights issue secured, costs cut 35%, and U.K. sales pipeline prioritized for rapid growth.BRAINPInvestor Update
Brain+
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Brain+ A/S, identified by the stock symbol BRAINP, is a healthcare company based in Copenhagen, Denmark, specializing in health information services. The company focuses on the development of digital therapeutics for Alzheimer's and dementia. Its product pipeline includes a variety of solutions aimed at cognitive stimulation therapy (CST) and computerized cognitive training for patients with mild cognitive impairment or early stages of Alzheimer's. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the Copenhagen Stock Exchange.